Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Every Build & Define protocol starts with a consultation, includes lab monitoring, and is adjusted based on your response
Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply
Sadly, its not a one-size-fits-all answer
Certain conditions can increase the risk of complications or change how medications work in your body
Nakagawa, T
Share this record with your PlexusDx healthcare provider
US$ 25.43
US$ 20.21
US$ 23.58
